Pranav Kataria

Pranav Kataria

Auto-generated profile, based on publicly available information

Pranav Kataria

Department of Periodontology University of Connecticut, School of Dental Medicine Farmington Connecticut USA

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2026 in Journal of Periodontology
Verified
Journal Article
Open access
HSHamoun Sabri
Hamoun Sabri
SBSahar Baniameri
Sahar Baniameri
PKPranav Kataria
Pranav Kataria
HAHend Abulatifa
Hend Abulatifa
Parham HazratiParham Hazrati
Parham Hazrati
Muhammad SalehMuhammad Saleh
Muhammad Saleh
Background: Periodontitis, a chronic inflammatory disease, is linked to systemic conditions such as cardiovascular and kidney disease. Serum α‐Klotho, an anti‐aging protein with anti‐inflammatory properties, has been associated with systemic diseases, but its role in periodontitis is unclear. This study evaluated the relationship between serum α‐Klotho levels and periodontitis severity while accounting for confounders. Methods: In this cross‐sectional study, data from 961 participants in the National Health and Nutrition Examination Survey (NHANES) database were analyzed. Periodontitis was classified into stages (I–IV) and grades (A–C) using the ACES (Application of the 2018 periodontal status Classification to Epidemiological Survey data) guidelines. Serum α‐Klotho levels were measured via enzyme‐linked immunosorbent assay (ELISA). Ordinal logistic regression assessed associations between α‐Klotho levels and periodontitis, adjusting for confounders such as age, smoking, comorbidities, and oral hygiene. The number of lost teeth was analyzed as a secondary outcome. Results: In both adjusted and unadjusted regression models, no significant association was found between α‐Klotho levels and periodontitis. Particularly, adjusted models revealed no significant association between α‐Klotho levels and periodontitis stage (OR = 1.0001, p = 0.547, 95% CI: 0.9997–1.0006) or grade (OR = 0.9996, p = 0.144, 95% CI: 0.9991–1.0001). Age, smoking, and comorbidities significantly predicted severity. Despite a weak negative correlation between α‐Klotho and tooth loss ( r = –0.07, p = 0.023), this association was no longer significant after adjustment. Conclusion: No significant association was found between serum α‐Klotho levels and periodontitis severity. Age, smoking, and comorbidities were key predictors, highlighting the multifactorial nature of periodontitis. Further longitudinal and mechanistic studies are needed to clarify whether α‐Klotho has a value as a biomarker of periodontal inflammation or disease progression.

23 July 2026 in Journal of Clinical Periodontology
Verified
Journal Article
Open access
PDF file
KKKhushboo Kalani
Khushboo Kalani
HSHamoun Sabri
Hamoun Sabri
MLMaaham Lodhi
Maaham Lodhi
PKPranav Kataria
Pranav Kataria
SPShivam Patel
Shivam Patel
Muhammad SalehMuhammad Saleh
Muhammad Saleh
Aim: To evaluate outcome measures in clinical studies on alveolar ridge augmentation (ARA) and map them to the Implant Dentistry Core Outcome Set and Measurement (ID‐COSM) framework and the Food and Drug Administration (FDA) terminology. Methods: A systematic search was carried out across four databases through June 2025. Randomised and non‐randomised clinical trials, prospective clinical studies, cohort studies and pilot clinical studies evaluating ARA performed before or simultaneously with implant placement were included. Extracted outcomes were mapped to ID‐COSM domains, subdomains and specific outcomes, and all were classified into FDA‐style outcome types. Risk of bias (RoB) was assessed using Domain 4 of RoB 2.0/ROBINS‐I, and associations between RoB and completeness of outcome reporting were analysed with Spearman's rank correlation and Kruskal–Wallis tests (α = 0.05). Results: Four hundred and twenty‐nine studies were included, predominantly randomised controlled trials (56.4%). Less than half of the studies fulfilled the mandatory ID‐COSM domains (47.6%), and none reported all nine subdomains. For mandatory outcomes, surgical complications (52.7%) and implant placement feasibility (48.3%) were more frequently reported than bone dimensional changes (33.8%), and peri‐implant bone stability was reported in only 11.0% of studies. For FDA categorisation, clinician‐reported outcomes (86.3%) and biomarkers (87.7%) predominated, while patient‐reported outcomes were reported in 31.9% of studies. Observer‐reported or performance outcomes were completely absent. Lower risk of bias was associated with more complete reporting of outcomes across domains, subdomains and specific outcomes ( p = 0.032, 0.017 and 0.009, respectively). Conclusion: Outcome reporting for ARA trials is highly heterogeneous and poorly aligned with the standardised minimum outcomes recommended by ID‐COSM and FDA categorisation.